Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b58f981963f6d55d627139e778c4ef7b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2006-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b74a5c863f32d0b7e9b91ab0cbced756 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_566a9a1843400f0dbd79dbe09067b616 |
publicationDate |
2008-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-1907426-A2 |
titleOfInvention |
Novel anti-igf-ir antibodies and uses thereof |
abstract |
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I / Insulin hybrid receptor. |
priorityDate |
2005-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |